[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fcn9bUUr8qAMup3YElcNLvyS2ddLKPzcudMn3y7s7aBY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":41,"rows":48},"Rijnstate Hospital",[4],129,false,18,10,16877,1,108,[14,16,19,22,25,28,31,33],{"name":15,"count":9},"Morbid Obesity",{"name":17,"count":18},"Obesity",9,{"name":20,"count":21},"Abdominal Aortic Aneurysm",8,{"name":23,"count":24},"Bariatric Surgery",7,{"name":26,"count":27},"Bariatric Surgery Candidate",5,{"name":29,"count":30},"Chronic Obstructive Pulmonary Disease",3,{"name":32,"count":30},"Gastric Emptying",{"name":34,"count":30},"Obstructive Sleep Apnea",[36],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06184633","DUTCH Weight Control in Atrial Fibrillation Study","2026-05-01","Semaglutide 3.2 MG\u002FML",[42,43,44,45,46,47],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[49,74,115,137,163,189,207,233,258,276,306,330,356,374,392,416,442,460,478,505,532,550,584,609,639,657,675,702,730,748],{"intervention":40,"totalTrials":11,"cells":50},{"EARLY_PHASE1":51,"PHASE1":54,"PHASE2":56,"PHASE3":58,"PHASE4":60,"NA":72},{"trials":52,"activeCount":53},[],0,{"trials":55,"activeCount":53},[],{"trials":57,"activeCount":53},[],{"trials":59,"activeCount":53},[],{"trials":61,"activeCount":11,"soonestReadout":39},[62],{"nctId":37,"briefTitle":38,"status":63,"phases":64,"primaryCompletion":39,"completion":65,"start":66,"enrollment":67,"conditions":68,"interventions":71},"RECRUITING",[46],"2027-05-01","2024-07-21",280,[69,17,70],"Atrial Fibrillation","Weight Loss",[40],{"trials":73,"activeCount":53},[],{"intervention":75,"totalTrials":76,"cells":77},"Ferrous fumarate",2,{"EARLY_PHASE1":78,"PHASE1":80,"PHASE2":82,"PHASE3":84,"PHASE4":86,"NA":113},{"trials":79,"activeCount":53},[],{"trials":81,"activeCount":53},[],{"trials":83,"activeCount":53},[],{"trials":85,"activeCount":53},[],{"trials":87,"activeCount":53},[88,101],{"nctId":89,"briefTitle":90,"status":91,"phases":92,"primaryCompletion":93,"completion":93,"start":94,"enrollment":95,"conditions":96,"interventions":98},"NCT02271997","Optimizing Iron Suppletion After Roux-en-Y Gastric Bypass","COMPLETED",[46],"2017-06-06","2014-12-04",120,[97],"Iron Deficiency",[75,99,100],"Ferrous gluconate","Iron(III)carboxymaltose",{"nctId":102,"briefTitle":103,"status":91,"phases":104,"primaryCompletion":105,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":112},"NCT02228902","Iron Absorption Trial",[46],"2015-05","2015-05-04","2014-08",24,[110,23,111],"Iron Absorption","Roux- en -y Gastric Bypass",[75,99],{"trials":114,"activeCount":53},[],{"intervention":99,"totalTrials":76,"cells":116},{"EARLY_PHASE1":117,"PHASE1":119,"PHASE2":121,"PHASE3":123,"PHASE4":125,"NA":135},{"trials":118,"activeCount":53},[],{"trials":120,"activeCount":53},[],{"trials":122,"activeCount":53},[],{"trials":124,"activeCount":53},[],{"trials":126,"activeCount":53},[127,131],{"nctId":89,"briefTitle":90,"status":91,"phases":128,"primaryCompletion":93,"completion":93,"start":94,"enrollment":95,"conditions":129,"interventions":130},[46],[97],[75,99,100],{"nctId":102,"briefTitle":103,"status":91,"phases":132,"primaryCompletion":105,"completion":106,"start":107,"enrollment":108,"conditions":133,"interventions":134},[46],[110,23,111],[75,99],{"trials":136,"activeCount":53},[],{"intervention":138,"totalTrials":11,"cells":139},"Carboplatin",{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":161},{"trials":141,"activeCount":53},[],{"trials":143,"activeCount":53},[],{"trials":145,"activeCount":53},[],{"trials":147,"activeCount":53},[],{"trials":149,"activeCount":53},[150],{"nctId":151,"briefTitle":152,"status":153,"phases":154,"primaryCompletion":155,"completion":156,"start":157,"enrollment":108,"conditions":158,"interventions":160},"NCT02103244","Validation of an Adjusted Dosing Algorithm of Carboplatin","UNKNOWN",[46],"2015-09","2015-12","2014-09",[159],"Cancer",[138],{"trials":162,"activeCount":53},[],{"intervention":164,"totalTrials":11,"cells":165},"Nadroparin",{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":172,"PHASE4":174,"NA":187},{"trials":167,"activeCount":53},[],{"trials":169,"activeCount":53},[],{"trials":171,"activeCount":53},[],{"trials":173,"activeCount":53},[],{"trials":175,"activeCount":53},[176],{"nctId":177,"briefTitle":178,"status":153,"phases":179,"primaryCompletion":180,"completion":180,"start":181,"enrollment":182,"conditions":183,"interventions":186},"NCT02295150","Prophylaxis of Venous Thromboembolism After Bariatric Surgery",[46],"2015-06","2013-03",50,[15,184,185],"Thromboembolism","Bypass Complications",[164],{"trials":188,"activeCount":53},[],{"intervention":100,"totalTrials":11,"cells":190},{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":197,"PHASE4":199,"NA":205},{"trials":192,"activeCount":53},[],{"trials":194,"activeCount":53},[],{"trials":196,"activeCount":53},[],{"trials":198,"activeCount":53},[],{"trials":200,"activeCount":53},[201],{"nctId":89,"briefTitle":90,"status":91,"phases":202,"primaryCompletion":93,"completion":93,"start":94,"enrollment":95,"conditions":203,"interventions":204},[46],[97],[75,99,100],{"trials":206,"activeCount":53},[],{"intervention":208,"totalTrials":11,"cells":209},"Enoximone",{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":216,"PHASE4":218,"NA":231},{"trials":211,"activeCount":53},[],{"trials":213,"activeCount":53},[],{"trials":215,"activeCount":53},[],{"trials":217,"activeCount":53},[],{"trials":219,"activeCount":53},[220],{"nctId":221,"briefTitle":222,"status":223,"phases":224,"primaryCompletion":225,"completion":225,"start":226,"enrollment":30,"conditions":227,"interventions":230},"NCT04420455","The Effects of Enoximone in Acute Exacerbation COPD","TERMINATED",[46],"2021-12-21","2020-05-12",[228,208,229],"COPD Exacerbation","Phosphodiesterase Inhibitor",[208],{"trials":232,"activeCount":53},[],{"intervention":234,"totalTrials":11,"cells":235},"Hydroxocobalamin",{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":244,"NA":256},{"trials":237,"activeCount":53},[],{"trials":239,"activeCount":53},[],{"trials":241,"activeCount":53},[],{"trials":243,"activeCount":53},[],{"trials":245,"activeCount":53},[246],{"nctId":247,"briefTitle":248,"status":91,"phases":249,"primaryCompletion":250,"completion":250,"start":251,"enrollment":182,"conditions":252,"interventions":254},"NCT02270749","Vitamin Deficiencies and Suppletion in Morbid Obesity",[46],"2016-06","2014-10",[253],"Vitamin B12 Deficiency",[234,255],"FitForMe vitamin B12",{"trials":257,"activeCount":53},[],{"intervention":255,"totalTrials":11,"cells":259},{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":266,"PHASE4":268,"NA":274},{"trials":261,"activeCount":53},[],{"trials":263,"activeCount":53},[],{"trials":265,"activeCount":53},[],{"trials":267,"activeCount":53},[],{"trials":269,"activeCount":53},[270],{"nctId":247,"briefTitle":248,"status":91,"phases":271,"primaryCompletion":250,"completion":250,"start":251,"enrollment":182,"conditions":272,"interventions":273},[46],[253],[234,255],{"trials":275,"activeCount":53},[],{"intervention":277,"totalTrials":11,"cells":278},"Radioactive iodine",{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":302,"NA":304},{"trials":280,"activeCount":53},[],{"trials":282,"activeCount":53},[],{"trials":284,"activeCount":53},[],{"trials":286,"activeCount":53},[287],{"nctId":288,"briefTitle":289,"status":223,"phases":290,"primaryCompletion":291,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":301},"NCT05142904","Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules",[45],"2024-11-01","2021-11-17",40,[295,296,297,298,299,300],"Thyroid Nodule, Toxic or With Hyperthyroidism","Autonomous Thyroid Function","Thyroid Nodule; Hyperthyroidism","Radiofrequency Ablation","Iodine Hyperthyroidism","Iodine Adverse Reaction",[277,277],{"trials":303,"activeCount":53},[],{"trials":305,"activeCount":53},[],{"intervention":307,"totalTrials":11,"cells":308},"Temazepam",{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":326,"NA":328},{"trials":310,"activeCount":53},[],{"trials":312,"activeCount":53},[],{"trials":314,"activeCount":53},[],{"trials":316,"activeCount":53},[317],{"nctId":318,"briefTitle":319,"status":91,"phases":320,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":325},"NCT00245661","Effects of Temazepam in Patients With Chronic Pulmonary Obstructive Disease",[45],"2007-08","2005-10",14,[29],[307],{"trials":327,"activeCount":53},[],{"trials":329,"activeCount":53},[],{"intervention":331,"totalTrials":11,"cells":332},"Novomix 30",{"EARLY_PHASE1":333,"PHASE1":335,"PHASE2":337,"PHASE3":339,"PHASE4":352,"NA":354},{"trials":334,"activeCount":53},[],{"trials":336,"activeCount":53},[],{"trials":338,"activeCount":53},[],{"trials":340,"activeCount":53},[341],{"nctId":342,"briefTitle":343,"status":91,"phases":344,"start":345,"enrollment":346,"conditions":347,"interventions":349},"NCT00151697","LANN-study: Lantus, Amaryl, Novorapid, Novomix Study",[45],"2005-05",150,[348],"Diabetes Mellitus Type II",[331,350,351],"Novorapid and Amaryl","Lantus",{"trials":353,"activeCount":53},[],{"trials":355,"activeCount":53},[],{"intervention":350,"totalTrials":11,"cells":357},{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":370,"NA":372},{"trials":359,"activeCount":53},[],{"trials":361,"activeCount":53},[],{"trials":363,"activeCount":53},[],{"trials":365,"activeCount":53},[366],{"nctId":342,"briefTitle":343,"status":91,"phases":367,"start":345,"enrollment":346,"conditions":368,"interventions":369},[45],[348],[331,350,351],{"trials":371,"activeCount":53},[],{"trials":373,"activeCount":53},[],{"intervention":351,"totalTrials":11,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":382,"PHASE4":388,"NA":390},{"trials":377,"activeCount":53},[],{"trials":379,"activeCount":53},[],{"trials":381,"activeCount":53},[],{"trials":383,"activeCount":53},[384],{"nctId":342,"briefTitle":343,"status":91,"phases":385,"start":345,"enrollment":346,"conditions":386,"interventions":387},[45],[348],[331,350,351],{"trials":389,"activeCount":53},[],{"trials":391,"activeCount":53},[],{"intervention":393,"totalTrials":11,"cells":394},"Letrozole",{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":412,"NA":414},{"trials":396,"activeCount":53},[],{"trials":398,"activeCount":53},[],{"trials":400,"activeCount":53},[],{"trials":402,"activeCount":53},[403],{"nctId":404,"briefTitle":405,"status":91,"phases":406,"primaryCompletion":407,"completion":407,"start":408,"enrollment":182,"conditions":409,"interventions":411},"NCT00138710","Short-term Effects of Aromatase Inhibition in Obese Men",[45],"2010-01","2005-08",[410,17],"Hypogonadotrophic Hypogonadism",[393],{"trials":413,"activeCount":53},[],{"trials":415,"activeCount":53},[],{"intervention":417,"totalTrials":11,"cells":418},"Intrathecal morphine at surgery, 0.1mg and placebo",{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":425,"PHASE4":438,"NA":440},{"trials":420,"activeCount":53},[],{"trials":422,"activeCount":53},[],{"trials":424,"activeCount":53},[],{"trials":426,"activeCount":53},[427],{"nctId":428,"briefTitle":429,"status":91,"phases":430,"completion":431,"start":432,"enrollment":95,"conditions":433,"interventions":435},"NCT00219921","Postoperative Analgesia After Total Hip Replacement",[45],"2007-02","2005-09",[434],"Total Hip Replacement",[417,436,437],"Patient Controlled Analgesia with iv morphine and placebo","intrathecal morphine AND patient controlled analgesia with iv morphine",{"trials":439,"activeCount":53},[],{"trials":441,"activeCount":53},[],{"intervention":436,"totalTrials":11,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":450,"PHASE4":456,"NA":458},{"trials":445,"activeCount":53},[],{"trials":447,"activeCount":53},[],{"trials":449,"activeCount":53},[],{"trials":451,"activeCount":53},[452],{"nctId":428,"briefTitle":429,"status":91,"phases":453,"completion":431,"start":432,"enrollment":95,"conditions":454,"interventions":455},[45],[434],[417,436,437],{"trials":457,"activeCount":53},[],{"trials":459,"activeCount":53},[],{"intervention":437,"totalTrials":11,"cells":461},{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":474,"NA":476},{"trials":463,"activeCount":53},[],{"trials":465,"activeCount":53},[],{"trials":467,"activeCount":53},[],{"trials":469,"activeCount":53},[470],{"nctId":428,"briefTitle":429,"status":91,"phases":471,"completion":431,"start":432,"enrollment":95,"conditions":472,"interventions":473},[45],[434],[417,436,437],{"trials":475,"activeCount":53},[],{"trials":477,"activeCount":53},[],{"intervention":479,"totalTrials":11,"cells":480},"Omeprazole rectally 1mg\u002Fkg",{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":487,"PHASE4":501,"NA":503},{"trials":482,"activeCount":53},[],{"trials":484,"activeCount":53},[],{"trials":486,"activeCount":53},[],{"trials":488,"activeCount":53},[489],{"nctId":490,"briefTitle":491,"status":91,"phases":492,"primaryCompletion":493,"completion":494,"start":432,"enrollment":495,"conditions":496,"interventions":500},"NCT00226044","Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.",[45],"2016-09","2017-09",17,[497,498,499],"Gastroesophageal Reflux","Esophageal Atresia","Hernia, Diaphragmatic",[479],{"trials":502,"activeCount":53},[],{"trials":504,"activeCount":53},[],{"intervention":506,"totalTrials":11,"cells":507},"Trizivir",{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":514,"PHASE4":528,"NA":530},{"trials":509,"activeCount":53},[],{"trials":511,"activeCount":53},[],{"trials":513,"activeCount":53},[],{"trials":515,"activeCount":53},[516],{"nctId":517,"briefTitle":518,"status":91,"phases":519,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":524,"interventions":526},"NCT00405925","FREE Study: Efficacy and Toxicity of Trizivir",[45],"2009-08","2009-09","2003-03",207,[525],"HIV Infections",[506,527],"zidovudine,lamivudine,abacavir",{"trials":529,"activeCount":53},[],{"trials":531,"activeCount":53},[],{"intervention":527,"totalTrials":11,"cells":533},{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":546,"NA":548},{"trials":535,"activeCount":53},[],{"trials":537,"activeCount":53},[],{"trials":539,"activeCount":53},[],{"trials":541,"activeCount":53},[542],{"nctId":517,"briefTitle":518,"status":91,"phases":543,"primaryCompletion":520,"completion":521,"start":522,"enrollment":523,"conditions":544,"interventions":545},[45],[525],[506,527],{"trials":547,"activeCount":53},[],{"trials":549,"activeCount":53},[],{"intervention":551,"totalTrials":76,"cells":552},"Diazoxide",{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":578,"PHASE4":580,"NA":582},{"trials":554,"activeCount":53},[],{"trials":556,"activeCount":53},[],{"trials":558,"activeCount":53},[559,569],{"nctId":560,"briefTitle":561,"status":91,"phases":562,"primaryCompletion":563,"completion":563,"start":564,"enrollment":565,"conditions":566,"interventions":567},"NCT00631033","DZX Mediated Insulin Suppression in Obese Men",[44],"2011-12","2008-07",51,[17],[551,568],"Metformin + Diazoxide",{"nctId":570,"briefTitle":571,"status":91,"phases":572,"start":573,"enrollment":574,"conditions":575,"interventions":577},"NCT00151684","Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men",[44],"2004-11",25,[17,576],"Hyperinsulinism",[551],{"trials":579,"activeCount":53},[],{"trials":581,"activeCount":53},[],{"trials":583,"activeCount":53},[],{"intervention":585,"totalTrials":11,"cells":586},"Ghrelin",{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":603,"PHASE4":605,"NA":607},{"trials":588,"activeCount":53},[],{"trials":590,"activeCount":53},[],{"trials":592,"activeCount":53},[593],{"nctId":594,"briefTitle":595,"status":153,"phases":596,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":600,"interventions":602},"NCT05726240","RCT of Ghrelin in Stroke Patients",[44],"2024-12-31","2023-10",80,[601],"Stroke, Ischemic",[585],{"trials":604,"activeCount":53},[],{"trials":606,"activeCount":53},[],{"trials":608,"activeCount":53},[],{"intervention":610,"totalTrials":11,"cells":611},"Paracetamol",{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":633,"PHASE4":635,"NA":637},{"trials":613,"activeCount":53},[],{"trials":615,"activeCount":53},[],{"trials":617,"activeCount":53},[618],{"nctId":619,"briefTitle":620,"status":91,"phases":621,"primaryCompletion":622,"completion":623,"start":624,"enrollment":625,"conditions":626,"interventions":631},"NCT04028596","Measuring Blood Flow in the Brain After Epileptic Activity",[44],"2022-12-30","2023-04-15","2019-12-05",34,[627,628,629,630],"Epilepsy","Depression","Postictal Delirium","Electroconvulsive Therapy",[610,632],"Nimotop",{"trials":634,"activeCount":53},[],{"trials":636,"activeCount":53},[],{"trials":638,"activeCount":53},[],{"intervention":632,"totalTrials":11,"cells":640},{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":651,"PHASE4":653,"NA":655},{"trials":642,"activeCount":53},[],{"trials":644,"activeCount":53},[],{"trials":646,"activeCount":53},[647],{"nctId":619,"briefTitle":620,"status":91,"phases":648,"primaryCompletion":622,"completion":623,"start":624,"enrollment":625,"conditions":649,"interventions":650},[44],[627,628,629,630],[610,632],{"trials":652,"activeCount":53},[],{"trials":654,"activeCount":53},[],{"trials":656,"activeCount":53},[],{"intervention":568,"totalTrials":11,"cells":658},{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":669,"PHASE4":671,"NA":673},{"trials":660,"activeCount":53},[],{"trials":662,"activeCount":53},[],{"trials":664,"activeCount":53},[665],{"nctId":560,"briefTitle":561,"status":91,"phases":666,"primaryCompletion":563,"completion":563,"start":564,"enrollment":565,"conditions":667,"interventions":668},[44],[17],[551,568],{"trials":670,"activeCount":53},[],{"trials":672,"activeCount":53},[],{"trials":674,"activeCount":53},[],{"intervention":676,"totalTrials":11,"cells":677},"N-Acetylcysteine",{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":686,"NA":688},{"trials":679,"activeCount":53},[],{"trials":681,"activeCount":53},[],{"trials":683,"activeCount":53},[],{"trials":685,"activeCount":53},[],{"trials":687,"activeCount":53},[],{"trials":689,"activeCount":53},[690],{"nctId":691,"briefTitle":692,"status":223,"phases":693,"primaryCompletion":694,"completion":694,"start":695,"enrollment":696,"conditions":697,"interventions":701},"NCT00637624","N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy",[47],"2017-07","2008-03",69,[698,699,700],"Carcinoma, Non-Small-Cell Lung","Carcinoma, Small Cell Lung","Mesothelioma",[676],{"intervention":703,"totalTrials":11,"cells":704},"Ringers Lactate",{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":711,"PHASE4":713,"NA":715},{"trials":706,"activeCount":53},[],{"trials":708,"activeCount":53},[],{"trials":710,"activeCount":53},[],{"trials":712,"activeCount":53},[],{"trials":714,"activeCount":53},[],{"trials":716,"activeCount":53},[717],{"nctId":718,"briefTitle":719,"status":91,"phases":720,"primaryCompletion":721,"start":722,"enrollment":723,"conditions":724,"interventions":728},"NCT00550186","Effect of Preload on Bladder Retention Volume During Spinal Anesthesia",[47],"2007-12","2007-10",144,[725,726,727],"Diuresis","Bladder Retention Volume","Hypotension",[703,729],"HaemoHES 6%",{"intervention":729,"totalTrials":11,"cells":731},{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":736,"PHASE3":738,"PHASE4":740,"NA":742},{"trials":733,"activeCount":53},[],{"trials":735,"activeCount":53},[],{"trials":737,"activeCount":53},[],{"trials":739,"activeCount":53},[],{"trials":741,"activeCount":53},[],{"trials":743,"activeCount":53},[744],{"nctId":718,"briefTitle":719,"status":91,"phases":745,"primaryCompletion":721,"start":722,"enrollment":723,"conditions":746,"interventions":747},[47],[725,726,727],[703,729],{"intervention":749,"totalTrials":11,"cells":750},"Calcitonin",{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":757,"PHASE4":759,"NA":761},{"trials":752,"activeCount":53},[],{"trials":754,"activeCount":53},[],{"trials":756,"activeCount":53},[],{"trials":758,"activeCount":53},[],{"trials":760,"activeCount":53},[],{"trials":762,"activeCount":53},[763],{"nctId":764,"briefTitle":765,"status":91,"phases":766,"primaryCompletion":767,"start":768,"enrollment":769,"conditions":770,"interventions":772},"NCT00688077","FGF-23 Suppressibility by Calcitonin",[47],"2012-12","2008-05",49,[771],"Hypophosphatemia",[749]]